Zai Lab and Arbutus Biopharma are set to release their second-quarter financial results, with Zai Lab anticipating significant revenue growth and corporate profitability by 2025. Zai Lab's portfolio includes late-stage assets and over 15 commercial-stage products by 2028. Arbutus Biopharma is concentrating on developing therapeutics for viral diseases and is currently working on an RNAi therapeutic and an oral PD-L1 inhibitor for HBV. Both companies are set to provide updates on their financial performance and upcoming projects.

Biopharmaceutical Companies' Q2 Results